Enrollment was completed in a 20 patient investigator-initiated study in
Japan using adipose-derived stem and regenerative cells in breast
augmentation procedures. The study, which began November 2007, is
evaluating a procedure whereby a woman’s fat
tissue is enriched with her own adipose derived stem and regenerative
cells to create a natural filler. This technique is referred to as ‘cell-enhanced
reconstruction.’
The stem and regenerative cells in the study were made available at the
time of surgery using the Celution®
800 System, an investigational device from Cytori Therapeutics (NASDAQ:
CYTX). This independent, investigator-initiated study is being sponsored
by Tatsuro Kamakura, M.D., Chief Medical Officer of Cosmetic Surgery
Seishin in Japan. Results of the study will be available following a
nine month assessment of the primary endpoints of cosmetic improvement
and volume retention.
"Our clinic’s goal for this study was to
learn if cell-enhanced reconstruction is feasible for bilateral cosmetic
breast augmentation as an alternative to implants,”
said Dr. Kamakura. “We look forward to
assessing the procedure’s effect on volume
retention following the nine-month follow-up period as we believe that
cell-enhanced reconstruction could overcome the challenges often
associated with conventional, non-cell-enhanced fat grafting. We plan to
continue offering cell-enhanced reconstruction to our patients in Tokyo
and expand it to patients in our Osaka clinic as well.”
Fat, known medically as adipose tissue, is the body's richest known
source of regenerative cells. Adipose-derived regenerative cells include
adult stem cells in addition to other important cell types that have
been shown pre-clinically to improve tissue retention compared to non-
'cell enhanced' tissue transfers. For this reason, these cells
potentially may improve and simplify traditionally complex fat transfer
procedures as well as enable more predictable outcomes and graft
retention when applied to cosmetic and reconstructive surgery.
Cytori Therapeutics
Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader in
regenerative medicine. The company is dedicated to providing patients
with new options for reconstructive surgery, developing treatments for
cardiovascular disease, and banking patients' adult stem and
regenerative cells. The Celution® 800 System
is being introduced in Europe into the reconstructive surgery market
while the Celution® 900 System will be
launched in Japan for cryopreserving a patient's own stem and
regenerative cells. Clinical trials are ongoing in cardiovascular
disease and planned for spinal disc degeneration, gastrointestinal
disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include our
history of operating losses, the need for further financing, regulatory
uncertainties regarding the collection and results of, clinical data,
dependence on third party performance, and other risks and uncertainties
described under the "Risk Factors" in Cytori Therapeutics' Securities
and Exchange Commission Filings. We assume no responsibility to update
or revise any forward-looking statements to reflect events, trends or
circumstances after the date they are made.
Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytoritx.com
